Jorge O. Sanchez O.

Hem/Onc Fellow at @JacobiNCBHosp @EinsteinMed 🩸🧬🔬🫁 | Former Internal Medicine and Chief Resident @SBHBronx | IMG from 🇩🇴 |

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

👑 CROWN at 7 years.
➡️ Lorlatinib median PFS: still not reached.

7-yr PFS: 55% vs 3%.
HR 0.19.

Event-free at 2 years → 79% still progression-free at year 7.

Zero new brain metastases after month 30. IC HR 0.06. Only 5% discontinued for TRAEs.

I think this is what it is for a meaningful subset of ALK+ patients: functional cure. Really exciting! For me today most patients should be getting lorlatinib 1L for @ALKPositiveinc @LungCancerRx @ASCO #ASCO26

[Antonio Ocejo @ja_ocejo]

If you’re an #IMG who applied to Hem/Onc fellowship this past cycle, please consider filling out this quick survey.

The more we share our experiences, the better we can understand the challenges we face as #IMGs and support future applicants.

Would really appreciate your input 👇

@HemOncFellows @hemeoncfellow @IMG_Oncologists

[Jorge O. Sanchez O. @JorgeOct_]

@ja_ocejo @EvidenceOpen @UpToDate @TwoOncDocs @OncBrothers @OncMedEdCoP @HemOncFellows @wkhealth @Wolters_Kluwer Felicidades Antonio!! 👏🏿👏🏿👏🏿

[Papa Heme @Papa_Heme]

CD markers very simplified!

CD34+ = Blast

CD3+ = T-cell
CD19+ = B-cell
CD33+ = Myeloid

CD34+ = Acute leukemia (but which type?)

CD34+ CD19+ = B-ALL
CD34+ CD3+ = T-ALL

CD34+ CD33+ = AML

CD34- CD33+ = APL (promyelocyte differentiated one step above blast)”

[Nehemias Guevara-Rodriguez @NehemiasGuevar5]

RT 😂🌮
Hard to argue—NEOADAURA is definitely looking muy bueno so far. Exciting signal for EGFR+ early-stage NSCLC, even if we’re still waiting on long-term outcomes @dominicandoc2 @COlazagasti @mgonzalezvelMD @MomaVelez11 @IMG_Oncologists @EsmirnaPrzR @JorgeOct_ @Florez_Lab

[Nehemias Guevara-Rodriguez @NehemiasGuevar5]

@NarjustFlorezMD @TumorBoardTues @Latinamd @benlevylungdoc @StephenVLiu @LealTiciana @MMarmarelis @lungoncdoc @KelseyPanMD @BRicciutiMD @BrunaPellini @ADesaiMD @MPishvaian @dominicandoc2 #TumorBoardTuesday #LCSM
Great discussion.
Current approach:
👉 MRD-negative status does NOT change my rec to give adj osi in eligible stage II EGFR+ #NSCLC.
MRD is predictive—but not yet validated to guide treatment de-escalation.
Prospective MRD-guided trials are ongoing.

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

10/23 #TumorBoardTuesday @TumorBoardTues @MPishvaian
Importantly, osimertinib is currently the only adjuvant therapy in resected NSCLC to demonstrate a statistically significant overall survival benefit in a biomarker-defined population.
https://t.co/yL2StvOvwG
https://t.co/byVkv8A5QL

[Nehemias Guevara-Rodriguez @NehemiasGuevar5]

🧠✨ Happening TODAY!
Join us at 8 PM ET for a deep dive into early-stage #NSCLC & #NeoADAURA
Excited to join @NarjustFlorezMD — don’t miss it!

#TumorBoardTuesday #LungCancer
@oncodaily @Florez_Lab @mgonzalezvelMD @MomaVelez11 @dominicandoc2 @Arthur_Aung @JorgeOct_

[Michael Hofman @DrMHofman]

From how to read a clinical trial to... How We Read FDG PET/CT: 🩻

https://t.co/A9gVDDqp47

Totally different topic but still very important for oncology

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

🫁 My pick of 10 lung cancer trials that will define practice at #ASCO2026 @ASCO

From sunvozertinib in exon20ins to 7-year CROWN data to TRITON in STK11/KEAP1/KRAS; the data is coming.

Which one are you watching?

@OncoAlert @LungCancerRx @oncodaily @EGFRResisters @KRASKickers

[Dr Amol Akhade @SuyogCancer]

What are plenary sessions for ASCO 2026 ?
Titles are just out
Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

A MUST-READ!

This is probably one of my most important papers where I try to teach how to fish rather than offer fish.

How I Read a Clinical Trial Report?

BG’s primer for Busy Clinicians.

Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.

https://t.co/HJhZlsBpU2

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

Beyond ATRA syndrome →

We used to call it ATRA syndrome.
But the biology is bigger.

ATRA, ATO, IDH1/2 and FLT3 inhibitors all force leukemia to mature.
And when too many cells mature at once:

→ cytokines surge
→ endothelium activates
→ capillary leak begins

Clinical pattern:
Fever + hypoxia + fluid overload ≠ infection → think DS

Key principles:
🔥 Dexamethasone immediately
⚖️ Continue vs HOLD based on severity
🧠 Control the substrate
 → Hydroxyurea first-line
 → Gemtuzumab ozogamicin if needed

Steroids treat the syndrome.
Cytoreduction controls the fuel.

Miss that—and you’re treating smoke, not fire.

#AML #Hemetwitter

[Vinod BalachandranMD @TheVinodLab]

This is why we do the work! We’re hopeful that we can build on this progress and allow more patients to access these promising treatments.

[Anirban Maitra @Aiims1742]

The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge!
Also today afternoon.
#AACR26

[Mamtha Balla, MD, MPH, FACP @MamthaB]

Thanks @OncBrothers!!

[Anirban Maitra @Aiims1742]

🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!

AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O

[Jorge O. Sanchez O. @JorgeOct_]

@PoleDoctress Go for it!

[Bloodman @Bloodman]

If eos < 1,500 don’t worry about it! Redefining Hematology Referral Thresholds for Eosinophilia - Patel - European Journal of Haematology https://t.co/xbGQx6tJUZ

[Daniel Peters @DPetersMD]

Amazing to be a leukemia MD in this day & age. This is the timeline of new💊approvals in AML that I get to show our @MCG_AUG Heme/Onc fellows. The last decade has sure been exciting. What's next? #leusm #MedEd